-+ 0.00%
-+ 0.00%
-+ 0.00%

Why Is AXT (AXTI) Raising $545 Million For Tongmei Capacity Expansion?

Simply Wall St·10/30/2026 11:40:13
Listen to the news
  • AXT (NasdaqGS: AXTI) reported that its majority-owned subsidiary Tongmei has agreed private equity financing of up to RMB 3.67b, or about US$545m.
  • A prominent Asia-based asset manager is leading the funding round, which is earmarked to expand Tongmei's semiconductor substrate operations.
  • The capital is intended to increase Tongmei's indium phosphide manufacturing capacity to serve high-demand end markets in advanced chips.
  • Tongmei's RMB 3.67b financing for indium phosphide growth is important, but investors need to weigh other AXT factors too. Take a look at 3 warning signs (2 major) we have identified for AXT.

For readers tracking how chip supply chains are being rebuilt around AI hardware, it is worth comparing this move with other firms in related infrastructure plays through 54 AI infrastructure stocks.

NasdaqGS:AXTI Earnings & Revenue Growth as at Oct 2026
NasdaqGS:AXTI Earnings & Revenue Growth as at Oct 2026

AXT operates in the compound semiconductor niche, supplying specialized substrates that sit upstream of many advanced chip designs. This Tongmei funding is focused on the part of the supply chain that feeds higher performance materials into AI and high-speed communications hardware.

2 things going right for AXT that this headline doesn't cover.

What Tongmei’s funding means for the AXT Narrative

This financing mainly reinforces the bullish part of the AXT Narrative that focuses on indium phosphide capacity and process efficiency as key drivers of future upside. Tongmei securing up to RMB 3.67b for expansion lines up with the catalyst that expects higher utilization and tighter control of the supply chain to support AI and data connectivity demand. The move also speaks directly to the risk side. AXT is choosing to lean into its China based footprint and customer base rather than pull back, so the existing concerns around export permits, regulatory pressure, and customer concentration are not reduced by this deal.

See how these catalysts shape AXT's path to a $91.60 fair value.

The cleanest test of whether this new capital is working for shareholders sits in Tongmei’s indium phosphide metrics. Watch how much of AXT’s future quarterly revenue and earnings updates are tied to higher indium phosphide output and whether export related bottlenecks still show up in order timing and backlog conversion through 2027.

Add AXT to your Watchlist and get alerts as these catalysts play out.